MEDTECH REALITY CHECK #4
Regulatory clearance is only one part of market access. Clinical practice, reimbursement, adoption and economics can change where a product should launch first.
“Which market is fastest?” is only part of the question
When a company decides where to launch first, regulatory timing understandably receives a lot of attention.
If one route appears more familiar, less resource-intensive or potentially faster, it may look like the obvious first market.
That can be a sensible factor in the decision. It should not be the only factor.
Regulatory clearance or approval is an important milestone, but it does not by itself establish that a product will be adopted, reimbursed or commercially successful.
Clinical practice can change the attractiveness of a market
A device enters an existing healthcare system with established treatment pathways, professional guidance, purchasing processes, workflows and competing technologies.
Depending on the product, professional recommendations and standard-of-care practices can materially influence adoption.
If the technology sits outside established practice, requires significant workflow change or lacks evidence that clinicians consider relevant, commercialization may be more difficult even when the regulatory route itself is feasible.
That is why market selection should include an assessment of clinical fit rather than only the regulatory pathway.
Reimbursement belongs in the strategy early
Then comes the question that can be addressed surprisingly late: who pays?
The answer varies significantly by country, care setting, device type and business model. There may be an existing reimbursement route, payment may sit within a broader procedure or hospital budget, direct payment may be possible, or additional health-economic and clinical evidence may be needed before reimbursement is realistic.
The point is not that every medical device needs a dedicated reimbursement code. Many do not.
The point is that the payment mechanism and purchasing pathway should be understood early enough to influence market selection, evidence planning and pricing assumptions.
A faster regulatory route can still produce a slower commercial journey
Consider two hypothetical markets.
Market A appears to offer the more straightforward regulatory path, but clinical adoption is uncertain and the payment pathway is unclear. Market B may require more regulatory work, but the product fits a clearer clinical need and has a more credible route to adoption and payment.
Which market offers the better first launch?
That cannot be answered by comparing regulatory pathways alone.
The answer depends on the total market-access picture, including the product, intended claims, evidence, clinical practice, regulatory route, reimbursement, pricing and commercial model.
Build one market-access strategy
Regulatory, clinical, reimbursement and commercial strategy are often owned by different functions. Strategically, they should inform one another.
The intended claims influence the evidence needed. The evidence can influence clinician adoption and payer decisions. The reimbursement environment can influence pricing and commercial viability. Market conditions may influence which indication or population the company prioritizes. Those choices can, in turn, affect the regulatory plan.
This is why I would not ask only: “Where can we get regulatory clearance fastest?”
I would ask: “Where can this product realistically reach patients, fit clinical practice, be adopted, be paid for and support a viable business?”
Regulatory clearance matters enormously. It is just not the same thing as market access.
Market access is where product, evidence, regulation, clinical adoption and economics meet.
About this series
MedTech Reality Checks is a practical LinkedIn series by Nadira Salah, CEO & Founder of MedQR Consulting, drawing on 10 years of experience in medical-device QA/RA and work with startups and smaller MedTech companies. The series focuses on recurring decision points where product, clinical, regulatory and business strategy meet.